Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs State Street Technology Select Sector SPDR ETF — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B), while State Street Technology Select Sector SPDR ETF trades at $198.22 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 58.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| SLS | XLK | |
|---|---|---|
Market Cap | $2.27B | $132.55B |
Volume | 4,179,659 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $15.46 | $202.00 |
52-Week Low | $1.39 | $127.49 |
Enterprise Value | $2.14B | — |
Typical Hold Time | — | 49 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLK, the Technology Select Sector SPDR ETF, trades at $197.73, down 1.82% amid broader tech pressure. The technical outlook is bullish based on moving averages, with support at $196 and resistance at $201. Recent news highlights concentration risks in semiconductor holdings and competition from thematic AI ETFs.
The ETF faces headwinds from potential Fed rate hikes and sector rotation but benefits from strong AI investment themes. Risks include overconcentration in mega-cap tech and interest rate sensitivity, while its low expense ratio and diversified tech exposure offer a defensive growth play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
